Télécharger le supplément (250 p.) - KCE

More documents

Recommendations

Info

154 Médecine à l'acte / médecine au forfait - ANNEXES KCE Reports 85 S Source DF Type I SS Mean Square F Value Pr > F inv*PP0020 1 47501498 47501498 4.17 0.0411 VPO*aidsoc 1 68634515 68634515 6.03 0.0141 Source DF Type III SS Mean Square F Value Pr > F age 6 1333185223 222197537 19.51
KCE Reports 85 S Médecine à l'acte : médecine au forfait - ANNEXES 155 Parameter Estimate Standard Error t Value Pr > |t| age*im 85-+ ans 2 0.000000 B . . . age*inv 1-4 ans 1 -4439.711910 B 1814.464030 -2.45 0.0144 age*inv 1-4 ans 2 0.000000 B . . . age*inv 25-39 ans 1 -913.858719 B 1418.933015 -0.64 0.5196 age*inv 25-39 ans 2 0.000000 B . . . age*inv 40-64 ans 1 -2174.934384 B 1398.371357 -1.56 0.1199 age*inv 40-64 ans 2 0.000000 B . . . age*inv 5-24 ans 1 -4201.892389 B 1406.265549 -2.99 0.0028 age*inv 5-24 ans 2 0.000000 B . . . age*inv 65-74 ans 1 -5226.969715 B 1889.895387 -2.77 0.0057 age*inv 65-74 ans 2 0.000000 B . . . age*inv 75-84 ans 1 0.000000 B . . . age*inv 75-84 ans 2 0.000000 B . . . age*inv 85-+ ans 2 0.000000 B . . . age*aidsoc 1-4 ans 2 0.000000 B . . . age*aidsoc 25-39 ans 1 -2879.485926 B 1317.795559 -2.19 0.0289 age*aidsoc 25-39 ans 2 0.000000 B . . . age*aidsoc 40-64 ans 1 -3067.786267 B 1305.994885 -2.35 0.0188 age*aidsoc 40-64 ans 2 0.000000 B . . . age*aidsoc 5-24 ans 1 -2890.801523 B 1330.908194 -2.17 0.0299 age*aidsoc 5-24 ans 2 0.000000 B . . . age*aidsoc 65-74 ans 1 -4588.480104 B 1305.173989 -3.52 0.0004 age*aidsoc 65-74 ans 2 0.000000 B . . . age*aidsoc 75-84 ans 1 -3922.003805 B 1373.329640 -2.86 0.0043 age*aidsoc 75-84 ans 2 0.000000 B . . . age*aidsoc 85-+ ans 1 0.000000 B . . . age*aidsoc 85-+ ans 2 0.000000 B . . . im*inv 1 1 717.900790 B 238.492910 3.01 0.0026 im*inv 1 2 0.000000 B . . . im*inv 2 1 0.000000 B . . . im*inv 2 2 0.000000 B . . . im*PP0020 1 1 413.968470 B 129.505384 3.20 0.0014 im*PP0020 1 2 0.000000 B . . . im*PP0020 2 1 0.000000 B . . . im*PP0020 2 2 0.000000 B . . . im*prep 1 1 -1589.773230 B 831.225914 -1.91 0.0558 im*prep 1 2 0.000000 B . . . im*prep 2 1 0.000000 B . . . im*prep 2 2 0.000000 B . . . im*chom3 1 1 -710.323377 B 216.663698 -3.28 0.0010 im*chom3 1 2 0.000000 B . . . im*chom3 2 1 0.000000 B . . . im*chom3 2 2 0.000000 B . . . inv*PP0020 1 1 430.393594 B 211.404445 2.04 0.0418 inv*PP0020 1 2 0.000000 B . . . inv*PP0020 2 1 0.000000 B . . . inv*PP0020 2 2 0.000000 B . . . VPO*aidsoc 1 1 1237.741088 B 504.219358 2.45 0.0141 VPO*aidsoc 1 2 0.000000 B . . . VPO*aidsoc 2 1 0.000000 B . . . VPO*aidsoc 2 2 0.000000 B . . . The X'X matrix has been found to be singular, and a generalized inverse was used to solve the normal equations. Terms whose estimates are followed by the letter 'B' are not uniquely estimable. Standardisation Cohorte 2 - Biologerie et Imagerie cat104predit Mean 555.02
Page 1 and 2:
Comparaison du coût et de la quali
Page 3 and 4:
Comparaison du coût et de la quali
Page 5 and 6:
KCE Reports 85 S Médecine à l’a
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108: KCE Reports 85 S Médecine à l’a
Page 113 and 114: KCE Reports 85 S Médecine à l'act
Page 157: KCE Reports 85 S Médecine à l'act
Page 209 and 210:
KCE Reports 85 S Médecine à l'act
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
This page is left intentionally bla
Page 247 and 248:
KCE reports 1. Efficacité et renta
Page 249:
74. Oxygénothérapie Hyperbare: Ra
show all

Télécharger le supplément (250 p.) - KCE

Create successful ePaper yourself

Delete template?

Save as template?